ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations.
ABC transporters
ABCG2
BCRP
Drug-drug interactions
Efflux mechanism
Molecular dynamics simulations
Journal
Computational and structural biotechnology journal
ISSN: 2001-0370
Titre abrégé: Comput Struct Biotechnol J
Pays: Netherlands
ID NLM: 101585369
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
05
2022
revised:
21
07
2022
accepted:
21
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
ABCG2/BCRP is an ABC transporter that plays an important role in tissue protection by exporting endogenous substrates and xenobiotics. ABCG2 is of major interest due to its involvement in multidrug resistance (MDR), and understanding its complex efflux mechanism is essential to preventing MDR and drug-drug interactions (DDI). ABCG2 export is characterized by two major conformational transitions between inward- and outward-facing states, the structures of which have been resolved. Yet, the entire transport cycle has not been characterized to date. Our study bridges the gap between the two extreme conformations by studying connecting pathways. We developed an innovative approach to enhance molecular dynamics simulations, 'kinetically excited targeted molecular dynamics', and successfully simulated the transitions between inward- and outward-facing states in both directions and the transport of the endogenous substrate estrone 3-sulfate. We discovered an additional pocket between the two substrate-binding cavities and found that the presence of the substrate in the first cavity is essential to couple the movements between the nucleotide-binding and transmembrane domains. Our study shed new light on the complex efflux mechanism, and we provided transition pathways that can help to identify novel substrates and inhibitors of ABCG2 and probe new drug candidates for MDR and DDI.
Identifiants
pubmed: 36016719
doi: 10.1016/j.csbj.2022.07.035
pii: S2001-0370(22)00315-4
pmc: PMC9389183
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4195-4205Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nat Struct Mol Biol. 2018 Apr;25(4):333-340
pubmed: 29610494
Int J Biochem Mol Biol. 2012;3(1):1-27
pubmed: 22509477
Sci Rep. 2021 May 12;11(1):10059
pubmed: 33980916
Nat Commun. 2021 Jul 19;12(1):4376
pubmed: 34282134
PLoS Comput Biol. 2022 Jan 26;18(1):e1009820
pubmed: 35081108
Biophys J. 2020 Nov 3;119(9):1833-1848
pubmed: 33086047
Front Mol Biosci. 2020 Jul 10;7:145
pubmed: 32754617
Cell Mol Life Sci. 2004 Mar;61(6):682-99
pubmed: 15052411
Nature. 2018 Nov;563(7731):426-430
pubmed: 30405239
Annu Rev Biochem. 2020 Jun 20;89:605-636
pubmed: 32569521
Cancer Lett. 2006 Apr 8;235(1):84-92
pubmed: 15990223
Nature. 2017 Jun 22;546(7659):504-509
pubmed: 28554189
J Pathol. 2002 Oct;198(2):213-9
pubmed: 12237881
Nature. 2018 Jan 18;553(7688):361-365
pubmed: 29320481
J Med Chem. 2018 Sep 13;61(17):7952-7976
pubmed: 30075623
Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42
pubmed: 21410427
J Comput Chem. 2010 Mar;31(4):671-90
pubmed: 19575467
Cancer Res. 2001 Apr 15;61(8):3458-64
pubmed: 11309308
Br J Pharmacol. 2016 Feb;173(3):497-510
pubmed: 26507673
Front Pharmacol. 2019 Mar 05;10:208
pubmed: 30890942
J Biol Chem. 2002 Dec 13;277(50):47980-90
pubmed: 12374800
Curr Pharm Biotechnol. 2011 Apr;12(4):686-92
pubmed: 21118086
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
J Chem Phys. 2020 Jul 28;153(4):044130
pubmed: 32752662
Nucleic Acids Res. 2019 Jul 2;47(W1):W423-W428
pubmed: 31114872
Nat Commun. 2019 Feb 18;10(1):824
pubmed: 30778065
Cancer Res. 2004 May 1;64(9):3296-301
pubmed: 15126373
Cancer Drug Resist. 2021;4:784-804
pubmed: 34993424
J Mol Biol. 2021 Jun 25;433(13):166980
pubmed: 33838147
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
Cell Mol Life Sci. 2021 Mar;78(5):2329-2339
pubmed: 32979053
Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13
pubmed: 19135109
Nat Commun. 2020 May 8;11(1):2264
pubmed: 32385283
Mol Pharmacol. 2003 Sep;64(3):610-8
pubmed: 12920197
Nucleic Acids Res. 2017 Aug 21;45(14):8448-8462
pubmed: 28854739
Biochim Biophys Acta Biomembr. 2018 Apr;1860(4):818-832
pubmed: 29097275
Curr Opin Struct Biol. 2008 Dec;18(6):726-33
pubmed: 18948194
Sci Rep. 2017 Nov 14;7(1):15534
pubmed: 29138424
Clin Pharmacol Ther. 2013 Jul;94(1):52-63
pubmed: 23588305
Comput Chem. 1995 Sep;19(3):241-6
pubmed: 7551557
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946618
J Biol Chem. 2003 Jun 20;278(25):22644-9
pubmed: 12682043
mBio. 2020 Mar 17;11(2):
pubmed: 32184247
AAPS J. 2015 Jan;17(1):65-82
pubmed: 25236865
Proc Natl Acad Sci U S A. 1982 Feb;79(4):1346-50
pubmed: 16593164
Cell Mol Life Sci. 2016 May;73(9):1927-37
pubmed: 26708291
Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6
pubmed: 21890895
PLoS One. 2016 Oct 14;11(10):e0164426
pubmed: 27741279
AAPS J. 2013 Jul;15(3):629-45
pubmed: 23543602
Sci Rep. 2021 Jun 23;11(1):13129
pubmed: 34162941
Biochim Biophys Acta. 2007 Nov;1768(11):2698-713
pubmed: 17662239
J Chem Theory Comput. 2011 Jul 12;7(7):2284-95
pubmed: 26606496
Drug Discov Today. 2015 Jun;20(6):686-702
pubmed: 25615716
Chem Biol Drug Des. 2010 Jan;75(1):3-17
pubmed: 19878193
Protein Sci. 2006 Jul;15(7):1597-607
pubmed: 16815914
Bioinformatics. 2015 Dec 15;31(24):3930-7
pubmed: 26315915
Biophys J. 2015 Sep 15;109(6):1179-89
pubmed: 26255588
Front Mol Biosci. 2022 Feb 04;9:832847
pubmed: 35187088
FASEB J. 2020 Apr;34(4):4890-4903
pubmed: 32067270
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
Neuropharmacology. 2021 Mar 1;185:108453
pubmed: 33450275
J Chem Theory Comput. 2015 Jun 9;11(6):2755-67
pubmed: 26575568